Sector News

Shire considers takeover of Swiss biotech group Actelion -Sunday Times

June 8, 2015
Life sciences
(Reuters) – Pharmaceutical company Shire is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd Europe’s biggest biotech firm, Britain’s Sunday Times newspaper reported, citing unnamed sources.
 
An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources.
 
Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock’s Friday closing price of 132 francs.
 
Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An Actelion spokesman said the company did not comment on market rumours.
 
Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates.
 
At the time, the company’s chief executive told Reuters it had not received any outside interest to buy the company.
 
In April, Shire reported a better-than-expected 20 percent rise in first-quarter earnings, helped by the launch of the first drug to treat binge eating disorder.
 
($1 = 0.6549 pounds) (Reporting by William James; additional reporting by Joshua Franklin in Zurich; editing by Jane Merriman and Jason Neely)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).